---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-044496"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:15:20.005966+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses

## Summary
- First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.
- Second participant with transformed follicular NHL achieved CR at 8 weeks and remains in CR at 3 months.
- Third participant with DLBCL (CAR T-ineligible) achieved partial response at 8 weeks with lesion shrinkage.
- All three patients tolerated treatment well; no cytokine release syndrome or neurotoxicity reported.
- Data presented at 11th Global Summit on Hematologic Malignancies on April 6, 2024 by City of Hope PI Dr. Shouse.

## SEC filing metadata
- accession: 0001104659-24-044496
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/0001104659-24-044496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/tm2411143d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-044496
- JSON: https://secwatch.observer/filing/0001104659-24-044496.json
- Plain text: https://secwatch.observer/filing/0001104659-24-044496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.